| Bioactivity | HAT-IN-9 (compound 7b) is a histone acetyltransferase (HAT) inhibitor that targets the HAT of adenovirus E1A binding protein p300 with an IC50 value of 1.51 μM. HAT-IN-9 reduces H3K27Ac protein levels and interferes with the expression of related proteins in breast cancer. HAT-IN-9 acts synergistically with Doxorubicin, exhibiting increased potency in inhibiting growth and invasion[1]. |
| Target | IC50: 1.51 μM (HAT of Adenoviral E1A binding protein p300) |
| Name | HAT-IN-9 |
| Formula | C23H24ClNO2 |
| Molar Mass | 381.90 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lai R, et al. Novel berberine derivatives as p300 histone acetyltransferase inhibitors in combination treatment for breast cancer. Eur J Med Chem. 2024 Jan 6;266:116116. |